deucravacitinib
bms
['#1000', 'deucra']
kahlenberg et al. tyk2i deucravacitinib in sle. clinical efficacy (figure). deucravacitinib suppressed ifn production, ifn-responsive gene expression, ifn-inducible proteins, b cell markers,serological biomarkers. #acr22 abstr#1000 
Rheumatologist @stjamesdublin , Associate Professor @tcddublin , Acute Medicine, Vasculitis, ILD, Retired @Emeunet Executive Committee member, @rheum_covid CASC